Heron Therapeutics says its chemo-induced nausea drug successful in clinical trial
29 May 2015
1
Heron Therapeutics Inc said its experimental drug for the treatment of chemotherapy-induced nausea and vomiting (CINV) met its main goal in a late-stage trial.
The company, whose shares were up 41 per cent in extended trading, said it expected to re submit a marketing application for the drug to the US FDA in mid-2015.
Though the company had filed for marketing application for Sustol twice, the FDA had sought additional data.
The drug, Sustol, in combination with two other drugs, was compared with a standard-of-care three-drug regimen and the results revealed that the percentage of patients who achieved the main goal of complete response was significantly higher in the Sustol group.
